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ABSTRACT
Objective: To estimate the prevalence of off-label and unlicensed prescribing in pediatric inpatients with nephrotic syndrome in a major teaching 
hospital in Indonesia.
Methods: A retrospective study was conducted in study hospital using medical records from pediatric inpatients with nephrotic syndrome during the 
period of January-December 2015. Patient and prescribing data were collected, and drugs were classified as on-label or off-label/unlicensed based 
on the Indonesia National Drug Information (IONI). Thereafter, off-label drugs were categorized with a hierarchical system of age, indication, route 
of administration, and dosage.
Results: There were 1553 drugs with 94 different types of drug administered to 67 patients during the study period. The data uncovered that 
1023 (65.9%) of the drug prescriptions were used either off-label/unlicensed. Most off-label drugs (n=433, 42.4%) were from nondiuretics 
antihypertensive drugs. The most common drugs used in an off-label/unlicensed manner were prednisolone and lisinopril. The high rate of off-label 
drug use in children was mainly related to age (n=772, 75.5%). Pediatrics with nephrotic syndrome was vulnerable to off-label uses where every 
patient received at least two off-label drugs. It seems that off-label prescribing in pediatric with nephrotic syndrome was not influenced by age or 
gender as every patient received off-label drugs.
Conclusion: Despite the high prevalence of off-label use in pediatric patients with nephrotic syndrome, this use is supported by evidence-based 
prescribing. Further, there remains a need for supporting clinical trials for pediatric drugs and updating IONI as the standard drug information in 
Indonesia to provide complete product information for pediatric use.
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INTRODUCTION
It has been stated clearly that each medicine should be used in the 
rational manner, in which the medicines should be safe, effective, 
and affordable. One of the measures to support the rational use of 
medicine is ensuring the medicines are prescribed in correspond with 
their product labels. Drug label is the official information of a drug 
product provided by a pharmaceutical company during the registration 
process and approved by an authorized institution (i.e., Food and Drug 
Administration in the United States, National Agency of Food and Drug 
Control in Indonesia). In addition to evidence-based medicine, the drug 
label can be used by health-care professional as the guidance during 
their practice to benefit patients [1].
The term “off-labels” refers to use of a drug that is not included in the 
product labeling for that drug (unapproved indication, unapproved age 
range, unapproved dosage, or unapproved route of administration) [1]. 
Meanwhile, unlicensed prescribing is defined as the use of unregistered 
drugs or nonpharmacological substance as a medicine, modification/
reformulation of a licensed drug to obtain the desired dose or to ease 
its administration and formulation manufactured under a special 
license [2]. It is of importance to note that the absence of labeling 
in pediatric patients does not necessarily imply that the use of the 
medicine is inappropriate and unsupported by evidence. Rather, it 
possibly points out that evidence for drug safety and efficacy in the 
pediatric population has not been submitted for review or has not met 
the regulatory standards of “substantial evidence” for approval by the 
authorized institution [1]. As a result, off-label and unlicensed use of 
drugs has become a worldwide phenomenon, particularly in pediatric 
patients.
There are some main reasons for the scarcity of substantial evidence 
for supporting drug labeling in pediatrics. Clinical trials in children 
are limited due to ethical consideration and practical difficulties, 
especially when dealing with young children. Reluctance of parents to 
give permission for their children as the trial participants has added 
another barrier for this matter. In addition, children merely account 
for the minority of the population in the drug market. From the 
economy perspective, it is not profitable for pharmaceutical industry to 
undertake extensive clinical trials in this population [3]. Consequently, 
a considerable number of medicines prescribed for children have 
not been studied specifically in the pediatric population and lack of 
pediatric information occurs. In addition, it is not uncommon that 
the dosages for children are extrapolated from data of clinical trials 
conducted in their counterpart population [4]. This situation may lead 
to children being referred to as “therapeutic orphans” [5].
It has been evident that off-label studies have been carried out in a 
range of pediatric settings, and intriguingly, the evident reveals a similar 
fact highlighting the high rate of off-label use in children [2,3,6-8]. 
However, it is interesting to note that limited studies have been done 
on the off-label drug use in the area of pediatric nephrology. Further, 
the information about the use of off-label drugs in pediatric, especially 
pediatric with nephrotic syndrome is still lacking. Nephrotic syndrome 
is responsible for one of the major chronic diseases in children, and 
subsequently, the patients should take their medicines for the long-
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term period [9]. Thus, this study aimed to estimate the prevalence 
of off-label and unlicensed prescribing in pediatric inpatients with 
nephrotic syndrome in a national referral hospital in Indonesia.
METHODS
A retrospective study was conducted in a 72-bed pediatric ward 
in a major teaching hospital in Indonesia during the period of 
January-December 2015. There were approximately 24,000 hospital 
admissions to the ward during the study period. The data were 
collected from medical records of pediatric patients with nephrotic 
syndrome hospitalized to pediatric ward during the study period. 
Patients with incomplete data were excluded. The data collected 
included patient characteristics (date of birth, sex, weight, height, past 
medical history, diagnosis, length of stay, and number of medications 
prescribed during hospitalization) and prescribing details (date of 
prescription data, dose, dosage form, strength of drug, and dosing 
frequency/interval). The patient’s age was classified according to the 
European Medicines Agency age classification: Newborns (0-27 days), 
infants and toddlers (28 days-23 months), children (2-11 years), and 
adolescents (12-18 years) [10].
Drugs were classified as on-label or off-label/unlicensed based on the 
Indonesia National Drug Information (IONI) 2015 [11]. Off-label drugs 
were categorized with a hierarchical system established by Hsien 
et al. [12] Categories of off-label were defined as follows:
•	 Age/weight:	Administration	of	a	prescribed	drug	outside	 the	age	
range or weight for which the product is licensed.
•	 Indication:	Prescribed	for	indication	not	mentioned	in	the	product	
label.
•	 Route	 of	 administration:	 The	 use	 of	 alternative	 routes	 of	
administration other than the approved route for that formulation 
in the product label.
•	 Dosage	(including	dose	and	frequency):	The	use	of	doses	or	dose	
frequencies not stated in the approved product label.
A drug was considered off-label if met at least one of the above criteria 
according to IONI 2015. A sequential approach was used for this study, in 
which all prescription drugs were initially analyzed for age. Drugs with 
no pediatric information or those prescribed for an age group for which 
the drug was not licensed were classified as off-label for age. The next 
level was indication, route of administration, and dosage subsequently. 
Once drugs were classified into a higher level (e.g. off-label category for 
age), those drugs were not analyzed for possible classification into any 
subsequent category [12]. Further, drugs were categorized unlicensed 
if they were unregistered drugs, unlicensed formulations of registered 
drugs or the use of nonpharmacological substances as medicines [2]. 
In case where a drug was classified both off-label and unlicensed, the 
final classification was off-label. The drugs were classified based on 
the WHO Anatomical Therapeutic Chemical (ATC) code. Prescriptions 
for parenteral nutrition, oxygen, and investigational drugs were not 
included.
Patient and prescribing-related data were summarized using descriptive 
statistics (mean±standard deviation or median [range] for variables 
measured on a continuous scale, and frequencies and percentages for 
categorical variables). The study protocol was approved by the Faculty 
of Pharmacy Pancasila University Institutional Review Board and 
Human Ethics Committee at the study hospital.
RESULTS
There were 67 patients who met the inclusion criteria during the study 
period, and the characteristics of patients and the diseases are outlined 
in Table 1. As shown in Table 1, patients ranged in age from 8 months 
to 17 years, and males constituted more than two-thirds of patients. 
In addition, there was notable variation in the length of hospitalization 
and the frequency of hospital admission. The data also uncovered 
the similar proportion of patients without complications and those 
with one complication, leaving around 22% with two complications. 
Hypertension and chronic kidney disease were the complications seen 
in these patients.
A total of 1553 drugs consisting of 94 different drugs were prescribed 
to 67 patients. The drugs included licensed, off-label, and unlicensed 
drugs. During hospitalization, on average the patients received 
20 drugs during the study period. Table 2 details the frequency of 
drugs in each ATC subcategory. It can be seen in Table 2 that drugs 
for cardiovascular system (n=653; 42.0%) accounted for the most 
frequent drugs prescribed for the patients, followed by various drugs 
(n=236; 15.2%) and antineoplastic and immunomodulating agents 
(n=227; 14.6%). Of the cardiovascular system drugs, antihypertensive 
drugs, (n=598; 91.6%), accounted for nearly all drugs in this class. In 
regards to “various” drug class, this class included vitamin, minerals, 
and their combinations. In addition, prednisone (n=125; 55.0%) 
dominated the antineoplastic and immunomodulating drug class; 
the remaining included methyl prednisolone, mycophenolic acid, and 
cyclosporine.
Our study uncovered that 1023 (65.9%) of the drugs were used either 
off-label (n=789, 50.8%) or unlicensed (n=234), 15.1%; leaving 34.1% 
as on-label drugs. The range of off-label/unlicensed use per patient was 
Table 1: Patients’ demographic characteristics and data related 
to disease
During the study period (N=67)
Patient characteristics Value
Age group (%)
Newborns (0-27 days 0
Infants and toddlers (28 days 23 months) 2 (2.9)
Children (2-11 years) 32 (47.8)




Median length of stay in days (range) 4 (1-46)
Median number of hospital admission (range) 1 (1-12)
Number of disease complications (%)
None 26 (38.8)
1 Complication 26 (38.8)
2 Complications 15 (22.4)
Table 2: Frequency of all drugs, including licensed, off‑label, and unlicensed drugs
Drug classification (n=1553) On‑label (n=530) (%) Off‑label (n=789) (%) Unlicensed (n=234) (%)
Cardiovascular system (n=653, 42.0%) 16 (2.5) 538 (82.4) 99 (15.2)
Various (i.e., vitamin, mineral, and 
electrolytes) (n=236, 15.2%)
206 (87.3) 11 (4.7) 19 (8.1)
Antineoplastic and immunomodulating 
agents (n=227, 14.6%)
9 (3.9) 157 (69.2) 61 (26.9)
Nervous system (n=157, 10.1%) 55 (35.0) 91 (57.9) 11 (7.0)
Alimentary tract and metabolism (n=132, 8.5%) 58 (43.9) 59 (44.7) 15 (11.4)
Anti-infectious for systemic use (n=89, 5.7%) 20 (22.5) 53 (59.6) 16 (17.9)
Respiratory system (n=49, 3.2%) 35 (71.4) 13 (26.5) 1 (2.0)
Musculo-skeletal system (n=10, 0.6%) 5 (50) 4 (4) 1 (10)
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2-101 drugs. When relating the patients’ demographic characteristics 
specifically age and gender, it appears that pediatric patients with 
nephrotic syndrome in this study were vulnerable to off-label uses 
where each patient received at least two off-label drugs. It seems that 
off-label prescribing in pediatric with nephrotic syndrome was not 
influenced by age or gender as every patient received off-label drugs. 
Further, there were 68 different off-label drugs and 35 unlicensed 
drugs prescribed. When all drugs were classified into their ATC 
classification categories (Table 2), cardiovascular drugs (82.4%), 
antineoplastic and immunomodulating agents (69.2%), and anti-
infectives (59.6%), respectively, constituted the highest percentages 
of off-label prescribing. Within specific ATC drug classes, it is shown 
in Table 2 that the top three percentages of unlicensed drugs were 
for antineoplastic and immunomodulating agents (26.9%), anti-
infectives (17.9%), and cardiovascular system (15.2%), respectively. 
The highest percentage of on-label drugs was documented from 
“various” drug classes (87.3%) specifically vitamins, minerals, and 
electrolytes. All unlicensed drugs were reformulated due to a lack of 
availability of a commercial preparation. Further, the 10 most common 
off-label and unlicensed drugs are shown in Table 3. In line with off-
label drugs, the most commonly prescribed unlicensed drugs were 
immunosuppressant (i.e., prednisolone) and antihypertensive agents 
(i.e., lisinopril, valsartan, and furosemide).
A hierarchical approach was used in assigning reasons for prescribing. 
Order of the hierarchy was age, indication, route of administration and 
dosage. Fig. 1 describes the reasons for off-label prescribing. As shown 
in Fig. 1, the high rate of off-label drug use in children was mainly 
related to age (n=596, 75.5%) and dosage (n=187, 23.7%), whereas 
the least common reason for off-label prescribing was due to indication 
(n=6, 0.8%). Further, this study did not find the route of administration 
as the reason for off-label use.
DISCUSSION
To the best of our knowledge, this study provides the first data in 
Indonesia on the prevalence of off-label and unlicensed prescribing 
in pediatric inpatients with nephrotic syndrome from a major 
general hospital. Our study uncovered the proportion of off-label and 
unlicensed prescribing were 50.8% and 15.1%, respectively. Thus, the 
overall extent of off-label unlicensed prescribing was 65.9%. It has 
been evident that the majority of off-label studies have been conducted 
on patients with varied reasons for admission. Little study has been 
done to specifically focus on nephrology patients. In comparison to 
other pediatric nephrology study, the percentage of off-label drugs in 
this study was considerably higher than that of reported by Yasinta 
et al. in a children’s hospital in China (overall: 16.6%, nephrotic 
syndrome: 19.7%). Yasinta et al. investigated the use of off-label 
drugs among patients admitted to a specialty ward with a range of 
nephrology-related diseases [9]. Likewise, when comparing the result 
with other nonnephrology pediatric studies, the off-label percentage in 
the present study was much higher than those documented in several 
overseas studies in the Switzerland (25%) [13], Malaysia (34%) [14], 
Netherlands, Sweden and Italy (39%) [15]. Nonetheless, similar findings 
were reported from studies in France (63%) [16] and Israel (55%) [17]. 
In terms of unlicensed prescribing, the result of our study was in line 
with a number of studies from different countries which reported the 
proportion of unlicensed drugs in a range of 8%-16% [17-20]. The high 
prevalence of off-label prescribing in the present study was likely due 
to the nature of specific diagnoses as the focus of investigation instead 
of including patients with a variety of medical conditions.
Current findings found immunosuppressant (i.e., prednisolone) and 
antihypertensive agents (i.e., lisinopril, valsartan, and furosemide) 
being responsible for the most frequent off-label and unlicensed 
drugs in pediatric inpatiens with nephrotic syndrome. The Kidney 
Disease: Improving Global Outcome group has released guidelines for 
management of pediatric nephrotic syndrome, and the guideline has 
been adopted by pediatric nephrologists worldwide. The guideline 
states that corticosteroids should be the mainstay treatment, in which 
the guideline recommends induction therapy with oral prednisone or 
prednisolone for 6 weeks followed with alternate-day maintenance 
therapy for another 6 weeks. After that, corticosteroid treatment can 
be ceased or tapered slowly in accordance to patients’ response [21]. In 
addition to steroids, diuretics may benefit patients with symptomatic 
edema. It has been evident that loop diuretics (e.g., furosemide) 
may improve troublesome edema which occurs quite frequently. 
Angiotensin-converting enzyme inhibitors or angiotensin II receptor 
blockers are often administered for resolving persistent hypertension 
and proteinuria. Nonetheless, some hypertensive patients may respond 
well to diuretics [21]. Treatment of nephrotic syndrome may also 
include management for lipid abnormalities, thromboembolism, and 
acute kidney failure [22-24].
It is important to note that off-label use of some drugs is clinically 
appropriate and justified by high-quality evidence [25]. The prescribing 
guideline in the study hospital has implemented evidenced-based 
medicine, in which the guideline has been prepared by comprehensively 
reviewing the recent evidence from both Indonesian and international 
clinical studies. Thus, off-label use of drugs, in this case, is justified as 
the clinicians in the study hospital have considered the reliable evidence 
and their clinical judgment when prescribing the drugs in the off-label 
manner. From legal perspective, there is no regulation yet in Indonesia 
as to the use of medicines outside their labels. However, it should be 
emphasized that clinicians should disclose the reasons for using the 
medicines in the off-label manner along with the supporting evidence. 
This information should be written in patients’ medical records for 
documentation and communicated to patients and/or their carers so 
they can make an informed decision [25]. In regards the reason for 
unlicensed prescribing, our study corresponded with other pediatric 
studies in which drug reformulation (so-called extemporaneously 
prepared drug [EPD]) was the main reason for unlicensed use. EPD 
Table 3: The 10 most common off‑label and unlicensed drugs
Off‑label drugs (N=789) Unlicensed drugs (N=234)
Drugs Frequency (%) Drugs Frequency (%)
Prednisolone 125 (15.8) Prednisolone 42 (17.9)
Lisinopril 121 (15.3) Lisinopril 28 (11.9)
Valsartan 98 (12.4) Valsartan 23 (9.8)
Furosemide 78 (9.9) Furosemide 14 (6.0)
Methyl 
prednisolone
74 (9.4) Spironolactone 12 (5.1)
Amlodipine 72 (9.1) Methyl 
prednisolone
10 (4.3)
Carvedilol 39 (4.9) Omeprazole 10 (4.3)
Losartan 38 (4.8) Cetirizine 10 (4.3)
Omeprazole 37 (4.7) Co-amoxiclav 8 (3.4)
Digoxin 34 4.3) Amlodipine 7 (3.0)
Fig. 1: Reasons for off‑label prescribing showing the hierarchical 
classification used
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occurs due to the fact that the availability of a specific drug or dosage 
or formulation suitable for pediatric patients was very limited [26]. It 
is unfortunate that EPD use in practice was not supported by reliable 
and adequate information signifying the issue of quality assurance [27].
The reasons for off-label and unlicensed prescribing are mainly 
attributed to lack of quality clinical trials in children and subsequently 
inadequate pediatric labeling of drugs. In addition, the complex 
procedures in revising the approved drug information may exacerbate 
the situation leading to the extensive use of off-label drugs [27]. 
Nonetheless, it is noteworthy to realize that the scientific literature 
is often available and adequately supports the off-label use of certain 
medicines [28]. Thus, it can be understood that some countries such 
as the Unites States and European countries under the European 
Union have introduced the new legislation to facilitate the availability 
of evidence-based drug therapy for children. The legislation has 
encompassed many aspects including economic incentives for 
pharmaceutical industry to undertake clinical trials involving pediatric 
population, and pressure for national regulatory agencies and research 
organizations to ensure the performance of high ethical and scientific 
quality of pediatric clinical trials [29,30]. The legislation also focuses 
on the measure to resolve the complexity in updating the product 
information. Previously, the pharmaceutical industries should organize 
the clinical trials and submit the required documents to the regulatory 
agency if they want to revise the product information (i.e., adding the 
new indication). The revision process is complex and takes before 
authority approval. However, the updating process based on recent 
legislation can be done by reviewing the pediatric studies justifying the 
off-label use of the reviewed medicines. If the studies are justified, the 
regulatory agency may then update the product information [29,30]. 
Indonesia may undertake the similar attempts to resolve some issues 
related to off-label medicines in children, in particular, supporting 
pediatric clinical trials and updating the product information in IONI as 
the national drug information source.
A number of limitations need to be acknowledged in the present 
study. First, the hierarchical approach in classifying the off-label 
drugs suffered an issue where in some cases the proportion of drugs 
classified as off-label due to indication, route of administration or dose 
would have been higher if the approach had not been used. Further, 
the classification system may lower the proportion of unlicensed 
drugs reported in this study. Second, this study was conducted in one 
hospital, which diminishes the ability to generalize the findings. It is 
recommended future studies involve multiple institutions and possibly 
pediatric hospitals allowing the comparison between pediatric wards 
in general hospital and children’s hospital. In addition, this study 
uncovered difficulties to draw accurate comparison with other studies 
due to variations in settings, design, size, method, and operational 
definitions of off-label and unlicensed medications. Nevertheless, the 
findings of the present study may provide the overall view of off-label 
and unlicensed prescribing in the pediatric population.
CONCLUSION
Despite the high prevalence of off-label use in pediatric patients 
with nephrotic syndrome, this use is supported by evidence-based 
prescribing. Further, there remains a need for supporting clinical trials 
for pediatric drugs and subsequently updating IONI as the standard of 
drug information in Indonesia to provide complete product information 
for pediatric use.
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